Sarepta Therapeutics Inc
NASDAQ:SRPT

Watchlist Manager
Sarepta Therapeutics Inc Logo
Sarepta Therapeutics Inc
NASDAQ:SRPT
Watchlist
Price: 118.97 USD 0% Market Closed
Market Cap: 11.4B USD
Have any thoughts about
Sarepta Therapeutics Inc?
Write Note

Wall Street
Price Targets

SRPT Price Targets Summary
Sarepta Therapeutics Inc

Wall Street analysts forecast SRPT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SRPT is 187.55 USD with a low forecast of 80.8 USD and a high forecast of 229.95 USD.

Lowest
Price Target
80.8 USD
32% Downside
Average
Price Target
187.55 USD
58% Upside
Highest
Price Target
229.95 USD
93% Upside

SRPT Last Price Targets
Sarepta Therapeutics Inc

The latest public price target was made on Nov 7, 2024 by Kristen Kluska from Cantor Fitzgerald , who expects SRPT stock to rise by 40% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Kristen Kluska
Cantor Fitzgerald
167 USD
Upside 40%
1 month ago
Nov 7, 2024
Cantor Fitzgerald Upgrades Sarepta Therapeutics (SRPT) to Overweight
StreetInsider
Brian Skorney
Robert W. Baird
193 USD
Upside 62%
1 month ago
Nov 7, 2024
Sarepta Therapeutics (SRPT) PT Lowered to $193 at Baird
StreetInsider
Andrew Tsai
Jefferies
165 USD
Upside 39%
2 months ago
Oct 21, 2024
Jefferies Starts Sarepta Therapeutics (SRPT) at Buy
StreetInsider
Biren Amin
Piper Sandler
200 USD
Upside 68%
4 months ago
Aug 8, 2024
Sarepta price target lowered to $200 from $205 at Piper Sandler
TheFly
Gavin Clark-Gartner
Evercore ISI
179 USD
Upside 50%
4 months ago
Aug 8, 2024
Evercore ISI Upgrades Sarepta Therapeutics (SRPT) to Outperform
StreetInsider
Brian Abrahams
RBC Capital
181 USD
Upside 52%
4 months ago
Aug 8, 2024
Sarepta Therapeutics (SRPT) PT Lowered to $181 at RBC Capital
StreetInsider
Gena Wang
Barclays
203 USD
Upside 71%
4 months ago
Aug 8, 2024
Sarepta price target lowered to $203 from $226 at Barclays
TheFly
Brian Abrahams
RBC Capital
182 USD
Upside 53%
4 months ago
Jul 29, 2024
RBC Capital Upgrades Sarepta Therapeutics (SRPT) to Outperform
StreetInsider
Kostas Biliouris
BMO Capital
200 USD
Upside 68%
5 months ago
Jun 27, 2024
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
StreetInsider
Biren Amin
Piper Sandler
205 USD
Upside 72%
5 months ago
Jun 26, 2024
Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
StreetInsider
Gavin Clark-Gartner
Evercore ISI
185 USD
Upside 56%
5 months ago
Jun 24, 2024
Sarepta price target raised to $185 from $139 at Evercore ISI
TheFly
Uy Ear
Mizuho Securities
200 USD
Upside 68%
5 months ago
Jun 24, 2024
Sarepta Therapeutics (SRPT) PT Raised to $200 at Mizuho
StreetInsider
Brian Skorney
Robert W. Baird
200 USD
Upside 68%
6 months ago
Jun 21, 2024
Sarepta Therapeutics (SRPT) PT Raised to $200 at Baird, 'Best Case Label'
StreetInsider
Brian Skorney
Robert W. Baird
170 USD
Upside 43%
6 months ago
Jun 13, 2024
Pfizer failure eliminates DMD competitor for Sarepta, says Baird
TheFly
Gena Wang
Barclays
185 USD
Upside 56%
6 months ago
Jun 13, 2024
Pfizer failure removes overhang for Sarepta, says Barclays
TheFly
Biren Amin
Piper Sandler
157 USD
Upside 32%
6 months ago
Jun 13, 2024
Piper Sandler Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
StreetInsider
Kostas Biliouris
BMO Capital
170 USD
Upside 43%
6 months ago
Jun 7, 2024
BMO Capital Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
StreetInsider
Brian Abrahams
RBC Capital
142 USD
Upside 19%
6 months ago
May 28, 2024
RBC Capital Downgrades Sarepta Therapeutics (SRPT) to Sector Perform
StreetInsider
Brian Abrahams
RBC Capital
157 USD
Upside 32%
7 months ago
May 20, 2024
RBC 'somewhat surprised' Sarepta shares not stronger on Translarna news
TheFly
Uy Ear
Mizuho Securities
179 USD
Upside 50%
7 months ago
May 17, 2024
Sarepta Therapeutics (SRPT) PT Raised to $179 at Mizuho
StreetInsider
Hartaj Singh
Oppenheimer
180 USD
Upside 51%
7 months ago
May 14, 2024
Oppenheimer Upgrades Sarepta Therapeutics (SRPT) to Outperform
StreetInsider
Matthew Harrison
Morgan Stanley
165 USD
Upside 39%
7 months ago
May 6, 2024
Morgan Stanley Calls Sarepta Therapeutics (SRPT) a Catalyst Driven Idea: 'We see a 85% probability of a positive outcome, with SRPT potentially up 27%-50%'
StreetInsider
Brian Abrahams
RBC Capital
141 USD
Upside 19%
7 months ago
May 2, 2024
Sarepta Therapeutics (SRPT) PT Lowered to $141 at RBC Capital
StreetInsider
Matthew Harrison
Morgan Stanley
187 USD
Upside 57%
1 year ago
Mar 1, 2023
Why This Sarepta Therapeutics Is Turning Bullish
Benzinga
Show More Price Targets
Show Less Price Targets
Kristen Kluska
Cantor Fitzgerald
Price Target 167 USD
Upside/Downside 40%
View Source
Brian Skorney
Robert W. Baird
Price Target 193 USD
Upside/Downside 62%
View Source
Andrew Tsai
Jefferies
Price Target 165 USD
Upside/Downside 39%
View Source
Biren Amin
Piper Sandler
Price Target 200 USD
Upside/Downside 68%
View Source
Gavin Clark-Gartner
Evercore ISI
Price Target 179 USD
Upside/Downside 50%
View Source
Brian Abrahams
RBC Capital
Price Target 181 USD
Upside/Downside 52%
View Source
Gena Wang
Barclays
Price Target 203 USD
Upside/Downside 71%
View Source
Brian Abrahams
RBC Capital
Price Target 182 USD
Upside/Downside 53%
View Source
Kostas Biliouris
BMO Capital
Price Target 200 USD
Upside/Downside 68%
View Source
Biren Amin
Piper Sandler
Price Target 205 USD
Upside/Downside 72%
View Source
Gavin Clark-Gartner
Evercore ISI
Price Target 185 USD
Upside/Downside 56%
View Source
Uy Ear
Mizuho Securities
Price Target 200 USD
Upside/Downside 68%
View Source
Brian Skorney
Robert W. Baird
Price Target 200 USD
Upside/Downside 68%
View Source
Brian Skorney
Robert W. Baird
Price Target 170 USD
Upside/Downside 43%
View Source
Gena Wang
Barclays
Price Target 185 USD
Upside/Downside 56%
View Source
Biren Amin
Piper Sandler
Price Target 157 USD
Upside/Downside 32%
View Source
Kostas Biliouris
BMO Capital
Price Target 170 USD
Upside/Downside 43%
View Source
Brian Abrahams
RBC Capital
Price Target 142 USD
Upside/Downside 19%
View Source
Brian Abrahams
RBC Capital
Price Target 157 USD
Upside/Downside 32%
View Source
Uy Ear
Mizuho Securities
Price Target 179 USD
Upside/Downside 50%
View Source
Hartaj Singh
Oppenheimer
Price Target 180 USD
Upside/Downside 51%
View Source
Matthew Harrison
Morgan Stanley
Price Target 165 USD
Upside/Downside 39%
View Source
Brian Abrahams
RBC Capital
Price Target 141 USD
Upside/Downside 19%
View Source
Matthew Harrison
Morgan Stanley
Price Target 187 USD
Upside/Downside 57%
View Source
Show More Price Targets
Show Less Price Targets
Sarepta Therapeutics Inc Competitors:
Price Targets
ALNY
Alnylam Pharmaceuticals Inc
26% Upside
ZYME
Zymeworks Inc
31% Upside
MCRB
Seres Therapeutics Inc
332% Upside
BCYC
Bicycle Therapeutics PLC
164% Upside
BEAM
Beam Therapeutics Inc
73% Upside
ARTV
Artiva Biotherapeutics Inc
95% Upside
BPMC
Blueprint Medicines Corp
42% Upside
MNPR
Monopar Therapeutics Inc
8% Upside

Revenue
Forecast

Revenue Estimate
Sarepta Therapeutics Inc

For the last 8 years the compound annual growth rate for Sarepta Therapeutics Inc's revenue is 136%. The projected CAGR for the next 4 years is 38%.

136%
Past Growth
38%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Sarepta Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Net Income
Forecast

Net Income Estimate
Sarepta Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-16%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SRPT's stock price target?
Price Target
187.55 USD

According to Wall Street analysts, the average 1-year price target for SRPT is 187.55 USD with a low forecast of 80.8 USD and a high forecast of 229.95 USD.

What is Sarepta Therapeutics Inc's Revenue forecast?
Projected CAGR
38%

For the last 8 years the compound annual growth rate for Sarepta Therapeutics Inc's revenue is 136%. The projected CAGR for the next 4 years is 38%.

Back to Top